Want to join the conversation?
$AMGN 2Q15 Q&A: On the question about expansion of the Board asked by Flynn of Goldman Sachs, Bob said that the company is delighted to welcome Fred Hassan to the Board; he has terrific experience in the global biopharmaceutical industry and he shares Amgen’s enthusiasm for the innovation that is being generated and for long-term growth prospects.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.